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Abstract
Background: The high prevalence of anaemia and the increased morbidity and mortality associated with anaemia during
AIDS has been well described yet there has been little information about anaemia and changes in haemoglobin levels
during acute and early HIV-1 infection.
Methods: HIV-negative women (n=245) were enrolled into an observational cohort as part of the Centre for the AIDS
Programme of Research in South Africa (CAPRISA) Acute Infection Study. Acute infection was diagnosed following a positive
HIV RNA PCR in the absence of antibodies, or detection of HIV-1 antibodies within 3 months of a previously negative
antibody test. Haemotologic parameters were assessed before infection and at regular intervals in the first twelve months of
HIV infection.
Results: Fifty-seven participants with acute HIV infection were identified at a median of 14.5 days post-infection (range 10–
81) and were enrolled in the CAPRISA Acute Infection cohort at a median of 41 days post-infection (range 15–104). Mean
haemoglobin prior to HIV-1 infection was 12.7 g/dL, with a mean decline of 0.46 g/dL following infection. The prevalence of
anaemia increased from 25.0% prior to HIV-1 infection to 52.6% at 3 months post-infection, 61.1% at 6 months post-
infection, and 51.4% at 12 months post-infection.
Conclusions: Haematologic derangements and anaemia with a trend towards iron deficiency are common with acute HIV-1
subtype C infection in this small cohort. The negative impact of anaemia concurrent with established HIV infection upon
morbidity and mortality has been well documented but the prognostic potential and long-term effects of anaemia during
acute HIV-1 infection remain unknown.
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Introduction
Anaemia has been well described in established HIV-1
infection, with an estimated prevalence ranging from 10% in
asymptomatic HIV-infected patients to 92% in patients with
AIDS[1], but there is little data on red blood cell parameters
during the acute stages of HIV-1 infection. In established HIV
infection, lower haemoglobin levels have been shown to correlate
with decreasing CD4+ cell counts[2] and multiple studies have
found an association between anaemia during established infection
and a faster progression to AIDS and death [3–9]. Many of these
studies may be limited in their applicability to developing countries
as they were conducted in men with predominantly HIV-1
subtype B infection. However, a study from Tanzania found that
among women with World Health Organization (WHO) clinical
stage 1 or 2 disease, anaemia was associated with a more rapid
decline in CD4 cell count and an increased mortality [10]. The
high baseline rates of anaemia in many developing countries [11]
together with a growing AIDS epidemic could further increase the
burden of anaemia in these regions.
The aetiology of HIV-associated anaemia remains uncertain
but appears to be multifactorial. Potential mechanisms include
malnutrition, decreased haematopoietic cell production, dimin-
ished capacity of the haematopoietic stroma to respond to
increased demand, and impaired erythropoietin feedback second-
ary to excess inflammatory cytokines[1,12–15]. HIV-infected
patients have been noted to have reduced levels of serum iron
which would suggest iron-deficiency as the cause of the anaemia,
however microcytosis is rarely seen in these patients [1].
While there is limited data about anaemia during acute HIV
infection, it has been suggested that anaemia at the time of
seroconversion may have implications for the clinical progression
of the disease [16]. In a study of 42 seroconverters from Haiti,
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HIV disease progression.
The objective of this study was to describe the prevalence and
characteristics of anaemia during the first 12 months following
infection in a southern African population. We report on early
haematologic changes in a cohort of 57 South African women with
acute HIV-1 subtype C infection, twenty-three of whom had
haematologic profiles available prior to infection.
Materials and Methods
Study Population
TheCentrefortheAIDSProgrammeof Research inSouth Africa
(CAPRISA) Acute Infection Study is a prospective observational
cohort study of reproductive age women that will provide
information about the clinical, immunological, and virological
natural history of HIV-1 subtype C infection. HIV-uninfected
women at high risk of infection were recruited into an HIV-negative
cohort where they received extensive risk reduction counseling
including condom provision and underwent monthly HIV testing.
Women from the cohort with evidence of new HIV-1 infection on
monthly testing were enrolled into the acute HIV infection phase of
the study. In addition, seroconverters were also identified from other
studies on the basis of a positive HIV antibody test within 3 months
of a negative test. Participants with acute infection were followed
weekly for 3 weeks, fortnightly until 3 months, monthly until 1 year
post-enrollmentand every3 monthsthereafter.Any participant with
aC D 4 + cell count less than 350 cells/mm
3 at more than one study
visit was referred to an antiretroviral treatment program; none of the
women in this study took antiretrovirals at any time. Ethics approval
for this study was obtained from the Nelson Mandela School of
Medicine in Durban, the University of Cape Town, and the
University of Witwatersrand in Johannesburg, South Africa. Written
informed consent was obtained from all participants.
Clinical Data and Laboratory Methods
Participants in the HIV-negative cohort underwent a baseline
evaluationthatincluded a physical examination and bloodcollection
for a full haematological profile. Two HIV-1 rapid antibody tests
(Determine: Abbott Laboratories, Tokyo, Japan and Capillus;
Trinity Biotech, Jamestown, NY, USA) were performed on a
monthly basis and pooled PCR testing (Amplicor v1.5: Roche
Diagnostics, Rotkreuz, Switzerland) for HIV-1 RNA was performed
on all antibody negative samples. All samples identified to be HIV-
infected through the pooling assay were confirmed using a
quantitative RNA PCR (Amplicor v1.5) and an HIV enzyme
immunoassay (EIA) test (BEP 2000; Dade Behring, Marburg,
Germany)onthe sameand subsequent samples from theparticipant.
Acute infection was diagnosed following a positive HIV RNA
PCR in the absence of HIV-1 antibodies (i.e. pre-seroconversion)
or detection of HIV-1 antibodies within 3 months of a previously
negative antibody test. Time of infection was defined as 14 days
prior to a positive RNA PCR assay in the absence of HIV-1
antibodies or as the mid-point between the last HIV seronegative
test and the first HIV seropositive test.
Haemoglobin was measured using an Abbott Celldyne 3700
machine (Abbott Laboratories, Abbott Park, IL, USA) and
anaemia was defined as a haemoglobin value of less than 12g/
dL in keeping with the WHO definition[11]. Viral loads were
measured using the Amplicor v1.5 machine.
All analyses were conducted using the SAS statistical package
version 9.1 (SAS Institute, Cary, NC, U.S.A.). A paired t-test was
used to determine differences between groups at different time points.
Results
Between October 2004 and October 2006, 57 women with
acute HIV-1 infection were identified; 28 from the HIV-negative
cohort and 29 from other seroincidence studies. The mean age of
the women in the acutely HIV-infected cohort was 27.3 years
(standard deviation [SD] 8.70) and their mean body mass index
was 28.5 kg/m
2 (SD 7.15). The women with acute infection were
identified at a median of 14.5 days post-infection (range 10-81)
and were enrolled into the Acute Infection cohort at a median of
41 days post-infection (range 15–104).
For the 28 women from the HIV-negative cohort, the mean
pre-infection haemoglobin level was 12.7 g/dL (SD 1.40) and
eleven (39.3%) of them were anaemic; these results are
summarized in Table 1. From pre-infection to the first post-
infection study visit, the mean decline in haemoglobin was 0.46 g/
dL (SD 1.09). The mean decline in haemoglobin between
identification of acute infection and 3 months post-infection was
0.55 g/dL (SD 1.05) and between identification of acute infection
and 6 months post-infection was 0.93 g/dL (SD 1.16). For the 26
participants with data available at 12 months, there was a mean
increase of 0.10 g/dl (SD 0.97) between the 6 and 12 months post-
infection measurements. The prevalence of anaemia, as defined by
a haemoglobin level less than 12 g/dL, increased steadily
throughout the first 6 months following acute infection, reaching
61.1% at 6 months, and remained close to 51.4% at 12 months
post-infection (Figure 1).
Table 1. Haematologic parameters and median viral load prior to infection and by post-infection month.
Pre-seroconversion
(n=28)
Post-seroconversion*
(n=55)
3 months
(n=57)
6 months
(n=36)
9 months
(n=33)
12 months
(n=35)
Mean (SD) haemoglobin (g/dl) 12.68 (1.40) 12.36 (1.35) 11.81 (1.51) 11.39 (1.57) 11.39 (1.62) 11.41 (1.41)
%( #) with Anaemia (Hb,12g/dl) 25.0% (7) 43.6% (24) 52.6% (30) 61.1% (1722) 60.6% (20) 51.4% (18)
Mean (SD) MCV (fl) 85.60 (6.64) 83.97 (6.20) 83.68 (6.41) 80.86 (7.23) 79.83 (8.38) 81.72 (7.94)
Mean (SD) MCH (pg) 29.13 (2.75) 28.32 (2.55) 28.27 (2.68) 26.72 (2.89) 26.22 (3.02) 26.81 (3.02)
Mean (SD) RDW (%) 15.03 (1.34) 16.40 (2.00) 16.03 (1.78) 16.31 (2.04) 17.16 (2.28) 17.18 (2.47)
Median (range) viral load
(copies/mL)
75600 (547–
5 510 000)
48 800 (269–
1 390 000)
45 300 (,400–
673 000)
49 400 (,400–
494 000)
33 600 (,400–
1 750 000)
Normal values are as follows: Hb 12.0–16.5 g/dl, MCV 76–99 fl, MCH 26–34 pg, RDW 11–16%. (*Note: The post-seroconversion visit refers to the first visit after
identification of acute infection and was at a median of 41.5 days post-infection (range 15–104). Also, since acute infections were identified at different time points, not
all participants have data at each month post-infection.)
doi:10.1371/journal.pone.0001626.t001
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mean corpuscular haemoglobin (MCH) were 85.60 fl and
29.13 pg and declined with acute HIV infection by 1.78 fl (SD
2.74) and 0.98 pg (SD 1.46) respectively. The MCV and MCH
had mean declines of 2.53 fl (SD 4.33) and 1.68 pg (SD 1.72)
between acute infection and 12 months post-infection respectively.
Meanwhile, the red cell distribution width (RDW) increased by
1.70% (SD 2.16) with acute infection and then increased by 0.73%
(SD 2.17) between acute infection and 12 months post-infection.
While the mean serum iron, vitamin B12, and folate did not
change significantly at the time of acute infection, over the course
of the first twelve months following infection, the mean iron
level dropped to below the lower limit of normal (Table 2). The
mean ferritin level increased marginally at the time of acute
infection from 65.13 ng/mL prior to infection to 79.09 ng/mL
with acute infection. The mean ferritin then declined steadily to
41.14 ng/mL at 6 months, and 38.09 ng/mL at 12 months
(p=0.0006 and p=0.0165 compared with seroconversion,
respectively).
To determine if anaemia was correlated to disease progression,
the relationship between viral load and haemoglobin level were
compared at various intervals using Pearson’s correlation coeffi-
cient. The Pearson’s correlation coefficient between the haemo-
globin value at 3 months and the viral load closest to the time of
HIV infection was significant at –0.2731 (p=0.0398). The
correlations between haemoglobin level closest to the time of
infection and haemoglobin rate of decline and the viral load at
various time points (closest to time of infection, 6 months post-
infection, and 12 months post-infection) were not significant.
Fifteen of the 57 women (26.3%) were anaemic at all of their
follow-up visits. When comparing this subset of women with the
rest of the group, there were no significant differences in their age,
body-mass index, CD4 cell count (either at the first post-infection
visit or the mean of all available visits), or median viral load. As
would be expected, the mean MCV (75.8 vs. 84.5 fl, p=,0.0001)
and the mean MCH (25.1 vs. 28.2 pg, p=,0.0001) were
significantly lower for the women anaemic at every follow-up visit
and the RDW (18.3% vs. 16.0%%, p=,0.0001) was significantly
Figure 1. Prevalence of anaemia (Hb,12g/dL) prior to (time=0) and in the months following acute HIV infection vs. median HIV
viral load (copies/mL). *Note: month 1 represents the first post-infection visit which occurred at a median of 42 days post-infection (range 16-86).
doi:10.1371/journal.pone.0001626.g001
Table 2. Iron studies.
pre-infection
(n=28)
acute infection
(n=57)
6 months post-infection
(n=43)
12 months post-infection
(n=37)
mean (SD) Fe (mmol/L) 10.79 (5.82) 9.64 (5.56) 7.93 (4.62) 7.58 (6.10)
mean (SD) B12 (pmol/L) 319.00 (105.08) 284.84 (164.07) 288.16 (141.4) 285.59 (129.07)
mean (SD) folate (nmol/L) 21.66 (10.73) 20.19 (8.08) 21.27 (7.29) 23.00 (10.09)
mean (SD) ferritin (ng/mL) 65.13 (55.82) 79.09 (87.73) 41.41 (42.97) 38.09 (42.35)
Normal ranges: Fe 9.0–30.4 mmol/L, B12 132–857 pmol/L, Folate .12.19 nmol/L, ferritin 20–300 ng/mL.
doi:10.1371/journal.pone.0001626.t002
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ferritin was lower (35.4 vs. 61.2 ng/mL, p=0.0107) for the
women anaemic at every visit as well.
Discussion
Thisstudydemonstratedadeclineinhaemoglobinlevelsfollowing
HIV-1 subtype C infection and a rise in the prevalence of anaemia
from 25.0% prior to HIV-1 infection to 52.6% at 3 months post-
infection, 61.1% at 6 months post-infection, and 51.4% at
12 months post-infection. The haemoglobin declined by 0.46 g/
dL at the time of acute infection, by 0.93 g/dL during the first
6 months following infection, and then by a mean of just 0.10 g/dL
in the subsequent 6 months. The mean haemoglobin was lowest and
the prevalence of anaemia was highest at 6 months post-infection.In
thefollowing6 months,thehaemoglobinlevelremainedlowanddid
not recover to pre-infection levels. This observation may reflect that
perturbations of haematopoiesis or of the red cell life cycle are
occurring early in the course of HIV infection and that these
parameters begin to stabilize at 6 months post-infection. Unfortu-
nately, reticulocyte counts were not obtained and so we can only
infer the haematopoietic response from the available parameters.
The anaemia of these participants trended towards microcytosis
and hypochromia and this trend persisted throughout the first
12 months following HIV-1 infection. The trend towards
microcytosis combined with the progressive decline in serum iron
levels and the elevated red cell distribution width (RDW) point
towards iron-deficiency as the most likely etiology of the anemia in
this cohort. Although the slight elevations in serum ferritin in this
cohort do not correspond with the typical profile of iron-
deficiency, ferritin is an unreliable indicator of underlying iron-
deficiency in the setting of acute infection.
Anaemia seen this early following acute infection could be
thought to reflect impaired haematopoiesis in the setting of early,
uncontrolled viral replication and an excess of inflammatory
cytokines[17], as shown by our results at the time closest to HIV
infection. There was no significant correlation between haemo-
globin level or rate of haemoglobin decline and viral load at 6 or
12 months post-infection.
Previous reports have suggested that there is an increased risk of
anaemia with more advanced HIV infection[5], however, here we
demonstrate that anaemia occurs with increasing frequency during
the early stages of HIV-1 infection. Whether this acute infection
associated anaemia will resolve during the typically latent period
prior to clinical AIDS remains to be seen. Furthermore, whether the
presence or severity of anaemia during acute HIV-1 infection will
predict anaemia in chronic infection and/or more rapid disease
progression also remains to be seen. Given the results of Deschamps
and colleagues in Haiti that anaemia at seroconversion predicted a
four-fold more rapid progression to AIDS[16] and the results of
other studies that have found anaemia at any point in HIV infection
to be an independent risk factor for decreased survival [18], anaemia
isapotentiallyearlyindicatorofmorerapidclinicalcourseand could
factor into clinical algorithms regarding antiretroviral initiation,
particularly in resource constrained settings. Additionally, in light of
the propensity for certain antiretroviral medications such as
Nevirapine and Zidovudine (AZT) to exacerbate underlying
anaemia, a high prevalence of anaemia in patients awaiting therapy
could factor into decisions regarding medication choice.
It will be important to confirm these results in other cohorts and
to continue to characterize the relationship between anaemia and
clinical course of HIV-1 infection as this cohort progresses into
established infection. Additionally, since this cohort was comprised
entirely of women, it is unknown if these same patterns will hold
true for men. Although since women are at greater baseline risk for
anaemia than men, it is important to characterize the increased
burden that HIV-infected women will face.
Anaemia is a common problem among South African women
and, according to our results, becomes more common with early
HIV-1 infection. The increasing prevalence of anaemia in this
population during early HIV-1 infection is concerning in light of
the detrimental impact of low haemoglobin on energy and
physical functioning [19]. Further prospective data is necessary to
define the significance of these findings and to determine the
impact of anaemia in acute infection on subsequent disease
progression. The ongoing CAPRISA Acute Infection study will
continue to follow the cohort described in this report to investigate
whether anaemia during acute HIV-1 infection has any long-term
consequences.
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